NO331227B1 - Lineaere basiske forbindelser som har NK-2 antagonistaktivitet, farmasoytiske formuleringer derav og anvendelse av samme for fremstilling av farmasoytiske formuleringer - Google Patents

Lineaere basiske forbindelser som har NK-2 antagonistaktivitet, farmasoytiske formuleringer derav og anvendelse av samme for fremstilling av farmasoytiske formuleringer

Info

Publication number
NO331227B1
NO331227B1 NO20042083A NO20042083A NO331227B1 NO 331227 B1 NO331227 B1 NO 331227B1 NO 20042083 A NO20042083 A NO 20042083A NO 20042083 A NO20042083 A NO 20042083A NO 331227 B1 NO331227 B1 NO 331227B1
Authority
NO
Norway
Prior art keywords
pharmaceutical formulations
preparation
same
antagonist activity
basic compounds
Prior art date
Application number
NO20042083A
Other languages
English (en)
Norwegian (no)
Other versions
NO20042083L (no
Inventor
Alessandro Giolitti
Antonio Guidi
Valerio Caciagli
Carlo Alberto Maggi
Maria Altamura
Danilo Giannotti
Alessandro Sisto
Valentina Fedi
Nicholas Harmat
Rossano Nannicini
Franco Pasqui
Original Assignee
Malesci Inst Farmacobiologica Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITFI20010203 external-priority patent/ITFI20010203A1/it
Priority claimed from ITFI20020104 external-priority patent/ITFI20020104A1/it
Application filed by Malesci Inst Farmacobiologica Spa filed Critical Malesci Inst Farmacobiologica Spa
Publication of NO20042083L publication Critical patent/NO20042083L/no
Publication of NO331227B1 publication Critical patent/NO331227B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
NO20042083A 2001-10-29 2004-05-21 Lineaere basiske forbindelser som har NK-2 antagonistaktivitet, farmasoytiske formuleringer derav og anvendelse av samme for fremstilling av farmasoytiske formuleringer NO331227B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITFI20010203 ITFI20010203A1 (it) 2001-10-29 2001-10-29 Composti lineari con caratteristiche basiche ad attivita' nk-2 antagonista,loro processi di sintesi e formulazioni che li contengono
ITFI20020104 ITFI20020104A1 (it) 2002-06-14 2002-06-14 Composti lineari con caratteristiche basiche ed attivita' nk-2 antagonista, loro processi di sintesi e formulazioni che li contengono
PCT/EP2002/012022 WO2003037916A2 (en) 2001-10-29 2002-10-28 Linear basic compounds having nk-2 antagonist activity and formulations thereof

Publications (2)

Publication Number Publication Date
NO20042083L NO20042083L (no) 2004-05-21
NO331227B1 true NO331227B1 (no) 2011-11-07

Family

ID=26332714

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042083A NO331227B1 (no) 2001-10-29 2004-05-21 Lineaere basiske forbindelser som har NK-2 antagonistaktivitet, farmasoytiske formuleringer derav og anvendelse av samme for fremstilling av farmasoytiske formuleringer

Country Status (37)

Country Link
US (1) US7273856B2 (pt)
EP (1) EP1442050B1 (pt)
JP (1) JP4511835B2 (pt)
KR (1) KR100958226B1 (pt)
CN (1) CN100413882C (pt)
AR (1) AR037044A1 (pt)
AT (1) ATE339439T1 (pt)
AU (1) AU2002351794B2 (pt)
BR (2) BRPI0213574B1 (pt)
CA (1) CA2464353C (pt)
CO (1) CO5580834A2 (pt)
CY (1) CY1105847T1 (pt)
DE (1) DE60214750T2 (pt)
DK (1) DK1442050T3 (pt)
EA (1) EA007855B1 (pt)
EG (1) EG24335A (pt)
ES (1) ES2272792T3 (pt)
HK (1) HK1063326A1 (pt)
HR (1) HRP20040360B1 (pt)
HU (1) HUP0402081A3 (pt)
IL (1) IL161649A0 (pt)
MX (1) MXPA04003974A (pt)
MY (1) MY130373A (pt)
NO (1) NO331227B1 (pt)
NZ (1) NZ533097A (pt)
PA (1) PA8557201A1 (pt)
PE (1) PE20030611A1 (pt)
PL (1) PL209411B1 (pt)
PT (1) PT1442050E (pt)
RS (1) RS52290B (pt)
SI (1) SI1442050T1 (pt)
SV (1) SV2004001370A (pt)
TN (1) TNSN04077A1 (pt)
UA (1) UA78975C2 (pt)
UY (1) UY27514A1 (pt)
WO (1) WO2003037916A2 (pt)
ZA (1) ZA200404163B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111029A1 (de) * 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Neue substituierte thiophencarbonsäureamide, deren herstellung und deren verwendung als arzneimittel
ITFI20040221A1 (it) * 2004-10-27 2005-01-27 Guidotti & C Spa Composizioni farmaceutiche a base di nk2 antagonisti per uso pediatrico
JP4012239B2 (ja) * 2006-01-11 2007-11-21 生化学工業株式会社 オキサゾロン誘導体
US20080227823A1 (en) * 2007-03-12 2008-09-18 Hassan Pajouhesh Amide derivatives as calcium channel blockers
IT1394304B1 (it) * 2009-05-21 2012-06-06 Malesci Sas Processo per la preparazione di ibodutant (men15596) e relativi intermedi
JP5929483B2 (ja) * 2011-05-10 2016-06-08 住友化学株式会社 植物の生長を促進する方法
US8778941B2 (en) 2011-06-24 2014-07-15 Amgen Inc. TRPM8 antagonists and their use in treatments
AP2013007331A0 (en) 2011-06-24 2013-12-31 Amgen Inc TRPM8 antagonists and their use in treatments
EP2671575A1 (en) * 2012-06-04 2013-12-11 Universität Regensburg Ras inhibitors
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
CA3220039A1 (en) 2021-06-14 2022-12-22 Jr. David St. Jean Urea derivatives which can be used to treat cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3711335A1 (de) * 1987-04-03 1988-10-20 Merck Patent Gmbh Aminosaeurederivate
US5164372A (en) 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
ES2153841T3 (es) 1992-08-13 2001-03-16 Warner Lambert Co Antagonistas de la taciquinina.
ITFI940009A1 (it) * 1994-01-19 1995-07-19 Menarini Farma Ind Antagonisti delle tachichinine, loro preparazione e formulazioni farmaceutiche che li contengono.
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
NZ287284A (en) * 1994-06-06 1998-10-28 Warner Lambert Co N-[2-(phenyl(substituted)ethylamino)-1-(indolylmethyl)-1-methyl -2-oxoethyl] carbamic acid ester derivatives, medicaments and intermediates
US5483070A (en) * 1994-08-02 1996-01-09 Packard Instrument Company Scintillation counter
IT1291776B1 (it) 1997-02-07 1999-01-21 Menarini Ricerche Spa Composti monociclici a quattro residui bifunzionali, aventi azione nk-2 antagonista
IT1291823B1 (it) 1997-04-08 1999-01-21 Menarini Ricerche Spa Composti pseudo-peptidici, loro preparazione ed uso in formulazioni farmaceutiche
KR20010014262A (ko) * 1997-06-30 2001-02-26 닛뽄카야쿠가부시키가이샤 신규 나프티리딘 유도체 또는 그 염
US6740682B2 (en) * 1997-08-29 2004-05-25 Tularik Limited Meta-benzamidine derivatives as serine protease inhibitors
US6262069B1 (en) * 1997-08-29 2001-07-17 Protherics Molecular Design Limited 1-amino-7-isoquinoline derivatives as serine protease inhibitors
IT1304898B1 (it) 1998-09-08 2001-04-05 Menarini Ricerche Spa Prodotti con caratteristiche basiche aventi attivita' antagonista sulrecettore nk-1 e loro impiego in preparazioni farmaceutiche
ATE303988T1 (de) * 1999-06-14 2005-09-15 Lilly Co Eli Inhibitoren von serin proteasen
IT1307809B1 (it) 1999-10-21 2001-11-19 Menarini Ricerche Spa Composti monociclici basici ad azione nk-2 antagonista, processi difabbricazione e formulazioni che li contengono.
GB0030305D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030303D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
US20050038692A1 (en) 2003-08-14 2005-02-17 Kane John Michael System and method for facilitating centralized candidate selection and monitoring subject participation in clinical trial studies

Also Published As

Publication number Publication date
EA007855B1 (ru) 2007-02-27
US20040259930A1 (en) 2004-12-23
EP1442050A2 (en) 2004-08-04
MXPA04003974A (es) 2005-01-25
EA200400588A1 (ru) 2004-08-26
CA2464353A1 (en) 2003-05-08
CN1578786A (zh) 2005-02-09
AU2002351794B2 (en) 2008-09-11
PA8557201A1 (es) 2003-06-30
PT1442050E (pt) 2007-01-31
ES2272792T3 (es) 2007-05-01
KR100958226B1 (ko) 2010-05-17
JP4511835B2 (ja) 2010-07-28
KR20050040815A (ko) 2005-05-03
HRP20040360B1 (hr) 2013-02-28
DK1442050T3 (da) 2007-01-08
NZ533097A (en) 2005-07-29
EG24335A (en) 2009-02-01
ATE339439T1 (de) 2006-10-15
SI1442050T1 (sl) 2007-04-30
ZA200404163B (en) 2006-01-25
HUP0402081A3 (en) 2007-05-29
UY27514A1 (es) 2003-06-30
DE60214750D1 (de) 2006-10-26
HUP0402081A2 (hu) 2005-02-28
EP1442050B1 (en) 2006-09-13
US7273856B2 (en) 2007-09-25
CY1105847T1 (el) 2011-02-02
PL209411B1 (pl) 2011-08-31
BR0213574A (pt) 2004-10-26
UA78975C2 (en) 2007-05-10
SV2004001370A (es) 2004-02-19
PL368824A1 (en) 2005-04-04
IL161649A0 (en) 2004-09-27
AU2002351794A2 (en) 2003-05-12
HK1063326A1 (en) 2004-12-24
CO5580834A2 (es) 2005-11-30
CN100413882C (zh) 2008-08-27
BRPI0213574B1 (pt) 2018-04-10
RS36504A (en) 2007-04-10
JP2005521638A (ja) 2005-07-21
WO2003037916A2 (en) 2003-05-08
NO20042083L (no) 2004-05-21
DE60214750T2 (de) 2007-09-13
WO2003037916A3 (en) 2004-02-12
TNSN04077A1 (en) 2006-06-01
MY130373A (en) 2007-06-29
PE20030611A1 (es) 2003-09-02
AR037044A1 (es) 2004-10-20
RS52290B (en) 2012-10-31
CA2464353C (en) 2013-05-28
HRP20040360A2 (en) 2004-08-31

Similar Documents

Publication Publication Date Title
NO20043702L (no) 8-azaprostaglandinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
NO20033384L (no) Farmasoytisk formulering
NO20033556L (no) Farmasöytiske formuleringer
DK1498411T3 (da) Diketohydrazinderivatforbindelser og medikamenter indeholdende forbindelserne som den aktive bestanddel
NO20033785D0 (no) Farmasöytisk formulering
NO20042807L (no) Farmasoytiske sammensetninger som innbefatter aktive vitamin D forbindelser
NO20035298D0 (no) CDK-inhiberende pyrimider, deres fremstilling og deres anvendelse som legemidler
FI20011478A0 (fi) Farmaseuttinen koostumus
PT1501534E (pt) Formulacoes farmaceuticas
DK1453517T3 (da) Farmaceutiske formuleringer med platinderivat
NO20042739L (no) Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan
NO20035627D0 (no) Farmasöytisk formulering
IS7051A (is) Lyfjasamsetningar
NO20054214D0 (no) Iminoeterderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
EE05385B1 (et) LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon
NO331227B1 (no) Lineaere basiske forbindelser som har NK-2 antagonistaktivitet, farmasoytiske formuleringer derav og anvendelse av samme for fremstilling av farmasoytiske formuleringer
FI20022128A (fi) Farmaseuttinen koostumus
NO20042502L (no) Farmasoytisk formulering omfattende bicalutamid
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
EE05380B1 (et) FenletanoolamiiniÁkristallivorm,ÁselleÁvalmistamineÁjaÁsedaÁsisaldavadÁfarmatseutilisedÁkompositsioonid
NO20041878L (no) Karboksylsyrederivat-forbindelser og legemidler inneholdende de samme som den aktive bestanddel.
IT1338456B1 (it) Procedimento per la preparazione di alchiluree da o ,d-dimetil ditiocarbonato
EE200300563A (et) Bensüülaminopürimidiiniühendid, nende kasutamine ja ravim
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet
NO20041236L (no) Farmasoytisk formulering

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees